Genesys Capital

Active

Overview

Genesys Capital is a venture capital firm founded in 2000, based in Toronto, specializing in early-stage investments in life sciences companies including biotechnology, medical devices, and pharmaceuticals. The firm has raised over $400 million across five early-stage funds and invested in 44 companies, achieving around 20 exits. Notable outcomes include the $2.4 billion acquisition of portfolio company Fusion Pharmaceuticals by AstraZeneca in 2024.

History

Genesys Capital was founded in 2000 in Toronto by partners including Damian Lamb and Kelly Holman. The firm has launched five early-stage venture funds, with the third institutional fund closed and actively investing as of recent years. It has completed over 20 exits from 36-44 portfolio companies and invested more than $250 million, with a recent highlight being the 2024 acquisition of Fusion Pharmaceuticals by AstraZeneca for $2.4 billion.

Notable Products

Genesys Capital Fund III - Third institutional fund focused on early-stage life sciences investments.
Investment in Fusion Pharmaceuticals - Founding Series A investor; acquired by AstraZeneca for $2.4B in 2024.
Investment in Profound Medical - Backer of MRI-guided ultrasound devices for incision-free therapies.

Reputation

Genesys Capital is regarded as one of Canada's more experienced life sciences VC teams with over 25 years of operations and a strong track record of exits. Professionals note its hands-on approach and network in healthcare, though its scale remains modest compared to larger North American funds. It maintains positive industry relationships evidenced by repeat investments and high founding investor rate of 80%.

Sources (5)